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We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA
AML-10 trial which included a total of 2157 patients, 15-60 years old, random-
ized to receive either daunorubicin (DNR, 50 mg/m2), mitoxantrone (MXR,
12 mg/m2), or idarubicin (IDA, 10 mg/m2) in addition to standard-dose cytarabine
and etoposide for induction chemotherapy and intermediate dose cytarabine for
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consolidation. Younger patients who reached complete remission with complete
(CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic
hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-
identical sibling donor; in all other cases, an autologous HSCT had to be adminis-
tered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall
survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant dif-
ference between the three randomized groups regarding OS was observed
(P = .38). In young patients, 15-45 years old, no treatment difference (P = .89)
regarding OS was observed, while in patients 46-60 years old, MXR and IDA
groups had a trend for a longer OS as compared to the DNR group (P = .029).
Among younger patients without a favorable MRC cytogenetic risk subgroup
who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical
sibling donor had higher 10-year and 15-year OS rates than those without. In
older patients who reached CR/CRi, the long-term outcomes of those with or
without a donor was similar. In conclusion, long-term outcomes of the study con-
firmed similar OS in the three randomized groups in the whole cohort of
patients.
1 | INTRODUCTION
Sixty to 80% of 15-60 years old patients with acute myeloid leuke-
mia (AML) achieve a complete remission (CR) after a combination of
cytarabine and an anthracycline such as daunorubicin (DNR),
mitoxantrone (MXR), or idarubicin (IDA).1 In order to compare the
relative efficacy of these three anthracyclines, the EORTC and
GIMEMA groups conducted a large international phase III random-
ized controlled trial (RCT) which started to enroll patients in 1993.2
With a median follow-up of 5.6 years, main observations were that
the use of different anthracyclines had no impact on outcomes in
patients with a HLA-identical sibling donor. However, disease-free
survival (DFS) and survival from CR were each longer in the MXR
and IDA arms than in the DNR arm in the subgroup of patients with-
out a donor.2
Still, the best post-remission treatment for younger AML patients
remains debated.1,3-5 Most prospective studies assessing the impact
of having a HLA-identical sibling donor on AML outcomes (“genetic
randomization”) according to cytogenetic risk have been reported
with a relatively short (≈5-6 years) median follow-up.6-8 This is a sig-
nificant gap in our knowledge as nonrelapse mortality (NRM) due to
complications of chronic graft-vs-host disease may occur well beyond
5 years post transplantation9 while late relapses are not infrequent in
patients not offered an allogeneic transplantation.10
We herein provide results of the very long-term follow-up of
patients included in the large EORTC/GIMEMA AML-10 trial.2 The
primary objective was to assess the long-term impact of the type of
anthracycline given in the induction chemotherapy. The secondary
objective was to evaluate, in patients who reached a CR/CRi, the dif-
ference in the long-term outcome of those who a HLA-identical donor
vs those without such a donor. Subgroup analyses by age and cytoge-
netic features were investigated.
2 | METHODS
2.1 | Study design
Details of the EORTC/GIMEMA AML-10 trial design have been reported
in the initial publication.2 Briefly, inclusion criteria comprised age 15 to
60 years; diagnosis of primary or secondary AML (including AML occur-
ring after myelodysplastic syndrome) other than French-American-British
M3; no evidence of severe concurrent cardiac, pulmonary, neurologic,
and metabolic diseases or uncontrolled infections; and adequate liver
(serum bilirubin level <2× upper normal limit) and renal (serum creatinine
<2× upper normal limit) function tests. Exclusion criteria included blast cri-
sis of chronic myeloid leukemia and AML supervening after other chronic
myeloproliferative diseases and other progressive malignant diseases.
Eligile patients were randomized to receive either DNR (50 mg/m2),
MXR (12 mg/m2), or IDA (10 mg/m2) on days 1, 3 and 5 in addition to
standard-dose cytarabine (25 mg/m2 bolus followed by 100 mg/m2
given as a continuous infusion daily for 10 days), and etoposide
(100 mg/m2 on days 1-5) for induction chemotherapy. Randomization
was stratified according to centre, age (15 to 45 years vs 46 to 60 years),
white blood cell count (<50 vs 50 to 249 vs ≥250 × 109/L), and WHO
performance status (0 to 2 vs 3 to 4) using a minimization technique.
A second cycle of induction was administered in patients who
achieved a partial response (PR). Patients who achieved a CR or a CR
with incomplete blood cell counts recovery (CRi) after one or two
courses of induction chemotherapy received a consolidation course
750 BARON ET AL.
with the same anthracycline as in the induction course. They also
received intermediate dose cytarabine (500 mg/m2 every 12 hours as
a 2-hour IV infusion on days 1-6). Younger patients, 15 to 45 (or 55,
according to centre policy) years old were then scheduled to undergo
an allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
first CR/CRi if they had a HLA-identical sibling donor. Younger
patients without a HLA-identical sibling donor as well as older
patients who reached a CR/CRi had to receive an autologous HSCT
(auto-HSCT) after consolidation chemotherapy.
Criteria for response and relapse followed the Report of the
National Cancer Institute-Sponsored Workshop.11 The primary end
point was overall survival (OS). Secondary end points included CR/CRi
rate after induction, the DFS and OS from CR/CRi and the rate of
completion of auto- and allo-HSCT.
2.2 | Ethic statement
The study was approved by the ethics committees of the participating
institutions and was conducted in accordance with the Declaration of
Helsinki. All participants gave their informed consent.
2.3 | Cytogenetic assessment
Cytogenetic examinations were performed at diagnosis. Cytogenetic
data were centrally reported according to International System for
Cytogenetic Nomenclature (ISCN) and centrally reviewed.2 For the
current analysis, cytogenetics were centrally re-reviewed, described
according to International System for Cytogenetic Nomenclature
(ISCN),12 and classified using the refined UK Medical Research Coun-
cil (MRC) classification13 as previously reported.14
2.4 | Statistical analyses
The duration of OS was calculated from the date of randomization
until death, of any cause. The DFS was calculated as the time from
CR/CRi until the first relapse or death, whichever occurred first. OS
from CR/CRi was calculated as the time from CR/CRi until death.
The Kaplan-Meier method was used to estimate these time-to-
event distributions and the Greenwood formula to compute SEs and
confidence intervals (CI) for the 10-year OS, OS and DFS from CR/CRi
rates.15 Logrank test was used to compare these time-to-event distri-
butions between groups and the Cox proportional hazards model to
compute the hazard ratio (HR) and its corresponding CI.15
The estimates of the cumulative incidences of relapse and of
death without relapse from the date of CR/CRi, along with their SEs,
were based on competing risk methods.16,17 For the comparisons of
cumulative incidences between groups, and for producing forest plots,
the Fine-Gray model was used.18
The comparison of the three randomized groups regarding OS
was performed at a two-sided significance level of 0.05, and the two
pairwise comparisons (MXR vs DNR and IDA vs DNR) were per-
formed at the 0.025 alpha level. In patients who reached CR/CRi, the
time-to-event outcome comparisons of the randomized groups for
donor vs no donor, and for subgroup analyses, the tests were per-
formed at a two-sided significance level of 0.01. For these compari-
sons, the 99% CIs of the HRs were provided. Same was done when
we combined the two experimental arms (IDA and MXR) - unplanned
analyses in the protocol - in order to produce forest plots for OS and
OS from CR/CRi. In this setting, a test of interaction between some
variables (eg, cytogenetic group or age) and the treatment group
(IDA/MXR vs DNR) or donor availability in a Cox model was under-




Between November 1993 and December 1999, a total of 2157
patients were randomly assigned in the trial (Figure S1).2 Median age
was 44 years (range, 15-60 years). Majority of patients had de novo
AML (n = 2064), the remaining secondary AML (n = 46) or therapy
related AML (n = 47). The characteristics of the patients were well bal-
anced between the three randomized treatment groups (Table S1).
Results were initially published with a median follow-up of 5.6 years.
In the current report, median follow-up was 11 years.
3.2 | Impact of the type of anthracycline
in the induction/consolidation chemotherapy
3.2.1 | Overall survival
The overall 5-, 10- and 15-year OS rates were 33.2%, 30.1% and
28.0% respectively. No significant difference between the three ran-
domized groups regarding OS was observed (P = .38; Figure 1A).
We first studied whether there was an impact of age on the
association between the type of induction treatment and OS
(as mentioned in the material and method section randomization was
stratified for patient age: < 46 vs ≥46 years) insuring the integrity of
this analysis. Age impacted (test for interaction: P = .13) the treatment
difference regarding OS (Figure S2A). In young (< 46 years) patients,
the OS was comparable in the three treatment groups (P = .89;
Figure 1B). While OS was shorter in patients ≥46 than <46 years old,
in older patients OS was prolonged in the MXR and IDA groups, as
compared to the DNR group (P = .07 for the three-arm comparison,
Figure 1C, and P = .029, for the comparison between MXR and IDA vs
DNR patients combined, HR 0.84, 99% CI 0.69-1.03), Figure S2A).
Results remained unchanged by further adjustments by age and MRC
cytogenetic risk group (data not shown).
As expected, the initial MRC cytogenetic risk group had an
important impact on OS. The 10-year OS rates were 56.5%,
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31.7% and 11.2% in the favorable, intermediate and adverse risk
group, respectively (Figure 1D). However, MRC cytogenetic risk
group had a limited impact on the treatment difference (test
for interaction: P = .26; Figure 2A), so within each cytogenetic
risk subgroup, treatment outcomes were quite homogeneous
(Figure S3A-D).
F IGURE 1 Kaplan–Meier plots for A, overall survival (OS) according to the randomized arm in the whole cohort. B, OS according to the
randomized arm in patients 15-45 years old. C, OS according to randomized arm in patients 46-60 years old. D, OS according to MRC cytogenetic
risk classification. E, OS from CR/CRi in the whole study population. F, OS from CR/CRi according to the randomized arm in patients 15-45 years
old. G, OS from CR/CRi according to the randomized arm in patients 46-60 years old
752 BARON ET AL.
F IGURE 2 Kaplan-Meier plots for overall survival (OS) from CR/CRi according to HLA-identical sibling donor availability A, in patients
15-45 years old. B, in patients 46-60 years old. C, in patients 15-45 years old and MRC favorable cytogenetic risk group; D, in patients
15-45 years old and MRC intermediate cytogenetic risk group; E, Forest plot for OS from CR/CRi according to donor availability: subgroup
analysis by MRC cytogenetic risk and age in patients 15-45 years old
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3.2.2 | Outcomes in patients who reached
a CR/CRi
A CR/CRi after one or two courses of induction chemotherapy was
achieved in 69% of DNR patients, 70% of MXR patients, and 67% of
IDA patients (Table S2). As expected, patients in the favorable cytoge-
netic risk group had a higher probability of achieving a CR/CRi (85%)
than those in the intermediate (74%) or adverse (52%) MRC cytoge-
netic risk group.
A HLA-matched sibling donor was found in 466 (32%) of 1472
typed patients who reached a CR/CRi (n = 1477; five patients were
not typed). An allo-HSCT was performed in 317 of these 466 patients
with a donor (68%). The allo-HSCT rate in patients with a donor was
similar in the three randomized groups. As expected, the allo-HSCT
rate was higher in patients ≤45 years (71%) than in those
46-60 years old (60%), Tables 1 and 2. Among 1006 patients without
a donor, an auto-HSCT was performed less frequently in patients
from the MXR (41%) or IDA (44%) arm than in those from the DNR
arm (53%) (P < .01). This was due to higher rate of withdrawals from
toxicity and/or lower success rate of sufficient stem cell collection in
the MXR and IDA arms in comparison to the DNR arm.2 As expected,
the auto-HSCT rate was higher in patients ≤45 years (53%) than in
those 46-60 years old (40%), Tables 1 and 2. In the latter group, the
auto-HSCT rate was 37%, 33% and 49% in the MXR, IDA and DNR
groups, respectively.
The 10-year DFS rates from CR/CRi were similar in the three
treatment groups: 31.6% in DNR patients, 36.9% in MXR patients,
and 36.9% in IDA patients, respectively (P = .15)(Table S2). There was
no significant impact of randomization arm on the relapse incidence
or on the incidence of NRM (Table S2), either. Ten-year OS rate from
TABLE 1 Patient characteristics, treatment applicability and outcomes according to HLA-identical sibling donor availability in patients
<46 years of agea
No donor n = 509 Donor n = 330
Age (years), n (%)
15- < 26 129 (25) 77 (23)
26-45 380 (75) 273 (77)
Assigned HSCT administered, n (%) 267 (53) 235 (71)
All patients (n = 839) HR (99% CI) P value
10-year DFS from CR/CRi rate, % (SE%) 36.6 (2.2) 47.7 (2.9) 0.76 (0.59-0.97) .003*
10-year incidence of relapse, % (SE) 54.4 (2.3) 33.8 (2.7) 0.55 (0.41–0.74) <.001**
10-year incidence of nonrelapse mortality, % (SE%) 9.0 (1.3) 18.6 (2.2) 1.92 (1.18–3.12) <.001**
10-year OS from CR/CRi rate, % (SE%) 42.6 (2.3) 53.5 (2.9) 0.79 (0.61–1.03) .02*
Outcome according to the refined MRC cytogenetic risk group13
10-year DFS from CR/CRi rate, % (SE%) HR (99% CI) P value
Not assessable (n = 281) 32.1 (4.2) 50.6 (4.9) 0.69 (0.45-1.07) .03*
Favorable (n = 129) 63.2 (5.5) 54.6 (7.3) 1.20 (0.59-2.45) .52*
Intermediate (n = 368) 33.2 (3.1) 49.5 (4.5) 0.66 (0.45-0.96) .004*
Adverse (n = 61) 8.1 (5.5) 25.4 (7.4) 0.62 (0.30-1.31) .096*
10-year cumulative incidence of relapse, % (SE%)
Not assessable (n = 281) 57.1 (4.4) 33.3 (4.6) 0.58 (0.34-0.99) .005**
Favorable (n = 129) 29.1 (5.2) 24.1 (6.1) 0.76 (0.31-1.90) .45**
Intermediate (n = 368) 58.6 (3.3) 31.9 (4.1) 0.44 (0.27-0.70) <.001**
Adverse (n = 61) 83.8 (7.4) 54.3 (8.4) 0.47 (0.21-1.05) .016**
10-year OS from CR/CRi rate, % (SE%)
Not assessable (n = 281) 41.0 (4.1) 56.3 (4.9) 0.71 (0.45-1.14) .06*
Favorable (n = 129) 69.3 (5.4) 60.5 (7.2) 1.35 (0.62-2.95) .32*
Intermediate (n = 368) 38.8 (3.3) 55.3 (4.5) 0.69 (0.46-1.03) .016*
Adverse (n = 61) 6.0 (5.3) 32.1 (8.4) 0.55 (0.25-1.18) .04*
Note: Forest plots of the hazard ratio by donor availability, according to age and cytogenetic MRC risk group are provided in the supplemental Figures
4A-D (four endpoints: DFS, incidence of relapse, incidence of death without relapse, OS from CR/CRi).
Abbreviations: CI, confidence interval; CR, complete remission; CRi, CR with incomplete blood recovery; DFS, disease-free survival; HSCT, hematopoietic
stem cell transplantation; MRC, UK Medical Research Council; N, number; OS, overall survival; SE, standard error; HR, hazard ratio.
aInformation missing for three patients.
*P value provided by the logrank test.
**P value provided by the Gray test.
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CR/CRi was 36.7% in DNR patients, 41.8% in MXR patients, and
43.3% in IDA patients, respectively (P = .052) (Table S2).
We also analyzed the impact of age, stratification factor for the
randomization, on the association between the type of induction
treatment and DFS and OS from CR/CRi. In young (≤ 45 years)
patients, the DFS from CR/CRi (P = .50) as well as OS from CR/CRi
(P = .46) were comparable in the three treatment groups (Table S2,
Figure 1F). In contrast, in older patients, who had globally worse out-
comes than younger patients, DFS from CR/CRi (P = .12) and OS from
CR/CRi (P = .04) were prolonged in the MXR and IDA arms as com-
pared to the DNR arm (Table S2, Figure S2B, Figure 1G).
Results were confirmed in multivariate analysis, where the treat-
ment comparison was adjusted by age and MRC cytogenetic risk
group (data not shown).
3.3 | Impact of having a HLA-identical sibling
donor in patients who reached a CR/CRi
3.3.1 | Patients ≤45 years
The comparison of outcomes following auto- vs allo-HSCT was first
assessed in a cohort of 839 patients ≤45 years of age who achieved a
CR/CRi after induction chemotherapy, who were HLA-typed, and
who mostly were given consolidation chemotherapy. A total of
330 patients had an HLA-identical sibling (donor group) while the
remaining 509 patients had not (Table 1). As shown in Figure 2A and
in Table 1, the 10-year DFS (HR 0.76, 99% CI 0.59-0.97), and OS from
CR/CRi (HR 0.79, 99% CI 0.61-1.03) rates were approximately 10%
higher in patients with a donor than in those without. This result was
due to a lower incidence of relapse (HR 0.55, 99% CI 0.41-0.74), and
despite an increased incidence of NRM (HR 1.92, 99% CI 1.18-3.12)
in the donor group (Table 1, forest plots Figure S4). Assessing the
impact of donor availability on the outcomes from CR/CRi according
to cytogenetic risk group, we observed that patients with a donor had
higher 10- and 15- year OS from CR/CRi rates in all but those in the
favorable MRC cytogenetic subgroup (Figure 2B-E). Finally, sensitivity
analyses using a Cox time-dependent model shows that patients who
received allo-HSCT had a longer DFS (HR 0.67, 99% CI 0.47-0.95)
and OS from HSCT (HR 0.77, 99% CI 0.54-1.11), compared to those
who received auto-HSCT.
3.3.2 | Patients 46-60 years
The impact between allo-HSCT and auto-HSCT was then assessed
in a cohort of 635 patients 46-60 years old, who achieved a
CR/CRi after induction chemotherapy, and who generally received
consolidation chemotherapy. A total of 136 patients had a HLA-
identical sibling (donor group) while 497 patients had not (donor
availability was unknown in two additional patients) (Table 2).
Among patients aged 46-60 years, 635 reached CR/CRi. The out-
comes (DFS and OS) of CR/CRi patients with a donor was only
marginally prolonged as compared to those without a donor
(Figure 2E). Indeed, the positive effect of decreased relapse inci-
dence (HR 0.66, 99% CI 0.45-0.97; P = .003) was neutralized by an
increased risk of death in CR/CRi (HR 1.66, 99% CI 1.0-2.75;
P = .013) (Table 2; forest plots in Figure S5). Results remained prac-
tically unchanged by adjusting the comparison by age, randomized
treatment and MRC cytogenetic risk group (data not shown).
Finally, sensitivity analyses using a Cox time-dependent model indi-
cated that similar DFS from HSCT (HR 0.85, 99% CI 0.54-1.33),
and OS from HSCT (HR 0.95, 99% CI 0.60-1.51) were obtained in
allo-HSCT compared to auto-HSCT recipients.
TABLE 2 Patient characteristics, treatment applicability and outcomes according to HLA-identical sibling donor availability in patients
46-60 years of agea
No donor N = 497 Donor N = 136
Age (years), n (%)
46-50 163 (33) 71 (52)
51-60 334 (67) 65 (48)
Assigned HSCT administered, n (%) 197 (40) 82 (60)
All CR/CRi patients (n = 635) HR (99% CI) P value
10-year DFS from CR/CRi rate, % (SE%) 26.1 (2.1) 32.7 (4.2) 0.86 (0.63-1.15) .18*
10-year incidence of relapse, % (SE) 59.0 (2.3) 42.7 (4.3) 0.66 (0.45–0.97) .003**
10-year nonrelapse mortality, % (SE%) 15.3 (1.7) 24.7 (3.8) 1.66 (1.00-2.75) .01**
10-year OS from CR/CRi rate, % (SE%) 31.0 (2.3) 37.0 (4.3) 0.92 (0.67-1.25) .46*
Note: Forest plots of the hazard ratio by donor availability, according to age and cytogenetic MRC risk group are provided in the supplemental Figures
3A-D (four endpoints: DFS, incidence to relapse, incidence of death without relapse, OS from CR/CRi).
Abbreviations: CI, confidence interval; CR, complete remission; DFS, disease-free survival; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation;
N, number; OS, overall survival; SE, standard error.
aInformation missing for two patients.
*P value provided by the overall logrank test.
**P value provided by the Gray test.
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4 | DISCUSSION
Here we report the long-term follow-up of one of the largest phase III
RCT comparing various anthracyclines in the remission induction and
consolidation treatment of AML. Further, we assessed the long-term
impact of allo-HSCT (in comparison to auto-HSCT) on outcomes in
patients who achieved a CR/CRi, using a “genetic randomization”
(ie, having a HLA-identical sibling donor or not).
First, with the long-term follow-up of the study, we confirmed
that there was no significant difference between the three random-
ized groups regarding OS in the whole study population. However, we
observed a trend for a higher 10-year OS rate in patients randomized
to receive MXR or IDA in the induction and consolidation, as com-
pared to those to receive DNR in the subgroup of patients 46 to
60 years of age. This was not the case in younger patients, possibly
because a higher proportion of younger patients received an allo-
HSCT, offsetting the insufficient efficacy of DNR in this subgroup of
patients. Furthermore, in the entire study population, patients ran-
domized in the MXR or IDA arms had also a trend for a higher 10-year
OS from CR/CRi rate than those in the DNR arm; the corresponding
increase was approximately 7% and 11%, respectively. These findings
were not yet clear when the study was first evaluated at a median
follow-up of 5.6 years, stressing the importance of reporting long-
term follow up of large RCT. Even at long-term follow-up our study
confirms the superiority of IDA over DNR regarding OS as reported
by a Cochrane meta-analysis of RCTs reported in 2015 including data
from 9549 patients.19 The lower 10-year OS rate observed with DNR
could be due to the fact that the dose of DNR used in the AML-10
trial (as well as in several trials included in the above-mentioned meta-
analysis) was suboptimal (DNR/IDA ratio of 5). Note, a recent phase
III trial observed similar outcomes in AML younger patients random-
ized to receive induction with cytarabine and high-dose DNR (90 mg/
m2 × 3 days) or IDA (12 mg/m2 × 3 days).20 In addition, superior out-
comes with higher than standard doses of DNR (90 vs 45 mg/m2)
were reported by the ECOG.21 Interestingly, a meta-analysis of RCT
performed in children, and adults <60 years of age (n = 3382) reported
in 2013 that the superiority of IDA for remission induction chemo-
therapy was restricted to RCT with a DNR/IDA ratio < 5.22 More
recently, the UK-NCRI group reported similar OS but higher 60-day
mortality with DNR 90 mg/m2 in comparison to DNR 60 mg/m2.23
Another observation of our study was that the feasibility of per-
forming an auto-HCT was higher in DNR than in IDA or MXR patients.
Interestingly, this did not translate to lower relapse risk in DNR patients
despite prior RCT from our group that demonstrated better outcomes
with auto-HCT than with additional chemotherapy.24
Late NRMs (due in a large part to complications of chronic graft-
vs-host disease) are not infrequent beyond 5 years post allo-HSCT,9
while more late relapses can occur in patients not offered an allo-
HSCT.10,24 In fact, a recent study by the European Society for Blood
and Marrow Transplantation has demonstrated that, among AML
patients who were disease free at least for 2 years after an auto-
HSCT, the 5- and 10-year incidences of relapse from auto-HSCT were
11% and 16%, respectively.25 Consequently, long-term follow-up of
studies assessing the impact of post-remission treatment with allo-
HSCT are of major interest. In studies where information on the donor
availability at the achievement of CR/CRi is not collected, the Mantel-
Byar method26 or Cox time-dependent model should be used. This is
to avoid the guarantee time bias in the outcome comparison of
patients who received allo-HSCT, vs the other CR/CRi patients. In
order to eliminate the bias of such comparison due to patients' selec-
tion, which is stricter for patients allografted, a prospective collection
of donor availability in CR/CRi patients is mandatory in well-
conducted studies, like RCT. The comparison based on the availability
HLA-match donor vs no donor (“genetic randomization”) provides an
unbiased assessment of the allo-HSCT outcome, so it became the gold
standard statistical method in this setting.27 Here, we observed that,
in the group of patients <46 years of age, those with a HLA-identical
sibling donor (71% of them received an allo-HSCT) had a lower risk of
relapse translating to higher 10-year and 15- year DFS and OS rates
from CR/CRi in all patients but those with favorable risk cytogenetics.
This occurred despite a higher NRM in patients with a donor. Interest-
ingly, the advantage of having a donor in the subgroup of patients
with intermediate-risk cytogenetics was not apparent at the time of
the initial report,6 further stressing the importance of long-term
follow-up studies.
While transplant-related mortality has dramatically decreased in
the last decades, one could argue on the continued relevance of our
donor vs no donor analyses. On the other hand, given the progresses
in alternative donor transplantation, the vast majority of patients have
nowadays a suitable donor. Consequently, studies comparing allo-
HSCT to auto-HSCT and/or chemotherapy using a donor vs no donor
genetic randomization are no longer feasible. Since reduction of NRM
will result in a higher benefit of having a donor, the message of our
paper that having a donor (and thus receiving an allo-HSCT) is benefi-
cial to patients with intermediate and adverse cytogenetic remains
true for transplanted patients. It should be however noted that the
decision of allo-HCT or not in patients with intermediate-risk cytoge-
netic is mainly based on FLT3-ITD and NPM1 status of leukemia, as
well as on persistence of not or measurable residual disease.
In patients 46 years of age or older, there was no overall benefit
of having a donor because the reduction of relapse in this group of
patients was offset by a higher NRM. Further, even within the sub-
group of patients <46 years old, the advantage of having a donor was
more pronounced in very younger patients (15 to 29 years) than in
those 30 to 45 years old. These observations might be due to the fact
that AML-10 trial was performed 20 years ago, before the develop-
ment of modern reduced intensity/toxicity or truly nonmyeloablative
conditioning regimen for transplantation.28 Further studies are
needed to assess the long-term impact of reduced intensity allo-HSCT
in older AML patients with intermediate or poor risk cytogenetic fea-
tures. Indeed, recent data have observed that post-remission treat-
ment with a nonmyeloablative allo-HSCT might prolong OS in AML
patients even above 60 years of age.29
In summary, to the best of our knowledge this study reports the
first evidence-based data with regard to long-term impact of
anthracycline-type and donor availability on outcomes in younger
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AML patients. Specifically, long-term follow-up of the EORTC/
GIMEMA AML-10 trial confirmed that, overall, similar outcomes were
obtained by using either DNR, MXR or IDA (at the studied dosages)
during induction and consolidation. In 46-60 years old patients who
reached CR/CRi, having a donor or not yielded similar outcomes;
however, MXR and IDA tended to provide better results than DNR
given at 50 mg/m2. In addition, in the group of younger patients with-
out favorable cytogenetic features who reached CR/CRi, the long-
term outcome was improved when an HLA-identical sibling donor
was available.
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